Study Details
A study to investigate how effective and safe Solifenacin Succinate Suspension is in treating children/adolescents aged 5 to less than 18 years with symptoms of overactive bladder (OAB) compared to a non-active drug
Clinicaltrials.gov ID
Astellas Study ID
905-CL-076
EudraCT ID
2011-002066-20
Condition
Overactive Bladder Disease
Phase
Phase 3
Age
5 years - 17 years
Sex
Female & Male
Product
N/A
Type
Interventional
Trial Dates
Jun 2012 - Jan 2014
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment number
189
A Phase 3, Double-Blind, Randomized, Multi-center, Placebo-Controlled Sequential Dose Titration Study to Assess Efficacy, Safety and Population Pharmacokinetics of Solifenacin Succinate Suspension in Pediatric Subjects from 5 to less than 18 years of Age with Overactive Bladder (OAB)
Study summary
Study documents
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for A study to investigate how effective and safe Solifenacin Succinate Suspension is in treating children/adolescents aged 5 to less than 18 years with symptoms of overactive bladder (OAB) compared to a non-active drug? Contact us by filling our your information to the right and we’ll respond to you.
Locations
Site: 1011
Providence, United States, 02906
Site: 3854
Kharkiv, Ukraine
Site: 5205
Mexico City, Mexico, C.P.06700
Site: 9103
Lucknow, India, 226003
Site: 5504
Campinas, Brazil, 13083-887
Site: 3851
Kyiv, Ukraine, 58001
Site: 3812
Novi Sad, Former Serbia and Montenegro, 21000
Site: 4604
Stockholm, Sweden, 17176
Site: 4403
Leeds, United Kingdom, LS1 3EX
Site: 5507
Campinas, Brazil, 13087-567
Site: 4605
Umea, Sweden, 90185
Site: 3206
Esneux, Belgium, 4130
Site: 3102
Utrecht, Netherlands, 3584 EA
Site: 4806
Poznan, Poland, 61-664
Site: 3209
Antwerp, Belgium, 2650
Site: 8201
Seoul, Republic of Korea, 120752
Site: 6301
Quezon City, Philippines, 1108
Site: 3204
Kortrijk, Belgium, 8500
Site: 9102
Nagpur, India, 440012
Site: 8204
Gwangju, Republic of Korea, 501757
Site: 5501
Santo Andre, Brazil, 090060-650
Site: 1006
Shreveport, United States, 71106
Site: 4803
Gdansk, Poland, 80-952
Site: 5506
Curitiba, Brazil, 80240-060
Site: 3103
Rotterdam, Netherlands, 3015 CE
Site: 5503
Porto Alegre, Brazil, 90035-003
Site: 4401
Sheffield, United Kingdom, S10 2TH
Site: 1005
Hamilton, Canada, L8N 3Z5
Site:8202
Seoul, Republic of Korea, 156707
Site: 4907
Gottingen, Germany, 37075
Site: 3205
Leuven, Belgium, 3000
Site: 4606
Gothenburg, Sweden, 41685
Site: 1001
Quebec, Canada, G1V 4G2
Site: 4905
Mainz, Germany, 55101
Site: 4404
London, United Kingdom, NW1 2BU
Site: 3903
Torino, Italy, 10126
Site: 1008
Tarrytown, United States, 10591
Site: 3302
Lille, France, 59037
Site: 1013
Saint Louis, United States, 63110
Site: 3207
Brussels, Belgium, 1020
Site: 3208
Charleroi, Belgium, 6000
Site: 2701
Johannesburg, South Africa, 1709
Site:8203
Daegu, Republic of Korea, 705717
Site: 4801
Warsaw, Poland, 04-736
Site: 9114
Jaipur, India, 302004
Site: 9001
Ankara, Turkey, 6100
Site: 9109
New Delhi, India, 110001
Site: 7002
Moscow, Russian Federation, 123317
Site: 3210
Leuven, Belgium, 3000
Site: 8206
Incheon, Republic of Korea, 400-711
Site: 5505
Sao Jose do Rio Preto, Brazil, 15090-000
Site: 1009
Durham, United States, 27710
Site: 4804
Lubin, Poland, 20-093
Site: 5502
Sao Paulo, Brazil, 05403-000
Site: 3853
Dnipropetrovsk, Ukraine, 49100
Site: 3810
Belgrade, Former Serbia and Montenegro, 11 000
Site: 3104
Zwolle, Netherlands, 8011 JW
Site: 4906
Frankfurt, Germany, 60435
Site: 9002
Izmir, Turkey, 35100
Site: 1007
Stanford, United States, 94305
Site: 1002
Montreal, Canada, H3H 1P3
Site: 3852
Donetsk, Ukraine, 83045
Site: 4504
Koge, Denmark, 4600
Site: 4503
Aalborg, Denmark, DK-9000
Site: 4601
Jonkoping, Sweden, 55185
Site: 4802
Wroclaw, Poland, 50-369
Site: 9004
Kocaeli, Turkey, 41380
Site:7001
Saint Petersburg, Russian Federation, 194100
Site: 1004
Toronto, Canada, M5G 1X8
Site: 4602
Stockholm, Sweden, 11883
Site: 7003
Saint Petersburg, Russian Federation, 194100
Site: 4805
Gdansk, Poland, 80-803
Site: 4904
Munich, Germany, 80337
Site: 3201
Gent, Belgium, 9000
Site: 4502
Kolding, Denmark, 6000
Site: 4902
Emmendingen, Germany, 79312
Site: 7004
Moscow, Russian Federation, 119991
Site: 4501
Aarhus N, Denmark, 8200
Site: 2703
Cape Town, South Africa, 7700
Site: 5203
Leon, Mexico, 37000
Site: 3811
Belgrade, Former Serbia and Montenegro, 11 000
Site: 4702
Trondheim, Norway, 7030
Site: 9104
Dehradun, India, 248140
Site: 4901
Marburg, Germany, 35043
Site: 9110
Bangalore, India, 560017
Site: 9108
Ahmedabad, India, 380007
Site: 9105
Hyderabad, India, 500018
Site: 4903
Bonn, Germany, 53105
Site: 3902
Firenze, Italy, 50134
Site: 5202
Mexico City, Mexico, 4530
Site: 4701
Bergen, Norway, 5021
Site: 1015
Albany, United States, 12208
Site: 3202
Antwerp, Belgium, 2020
Site: 3101
Nijmegen, Netherlands, 6525 GA
Site: 3203
Gent, Belgium, 9000
Site: 9005
Istanbul, Turkey
Site: 9003
Ankara, Turkey, 6100
Site: 1012
Phoenix, United States, 85032
Site: 3901
Roma, Italy, 165
Site: 4603
Skovde, Sweden, 54185
Site: 7005
Moscow, Russian Federation
Site: 5204
Mexico City, Mexico, 78218
Site: 3301
Paris, France, 75015
Site: 8207
Seoul, Republic of Korea, 110744
Site: 1014
Cincinnati, United States, 45229
Site: 3850
Kiev, Ukraine, 1103
The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website
© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.
POWERED BY:
